DMAQ · Deep Medicine Acquisition Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.02M | - | $4.11M | $4.31M | $5.39M | - | $3.43M | $5.27M | $5.01M | - |
| Cost of Revenue | $2.34M | - | $1.26M | $2.40M | $1.73M | - | $1.92M | $1.86M | $1.96M | - |
| Gross Profit | $2.68M | - | $2.85M | $1.91M | $3.66M | - | $4.31M | $2.57M | $3.05M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $3.18M | - | $3.34M | $2.64M | $2.73M | - | $1.58M | $2.02M | $1.83M | - |
| Total Operating Expenses | $3.98M | - | $3.96M | $3.78M | $4.90M | - | $3.44M | $361.0K | $4.00M | - |
| D&A | $491.9K | - | $14.7K | $12.6K | $115.3K | - | - | - | $36.1K | - |
| Operating Income | ($1.29M) | - | ($1.11M) | ($1.87M) | ($1.23M) | - | $872.3K | ($785.0K) | ($943.7K) | - |
| Interest Expense | $207.2K | - | $108.3K | $1.52M | $38.9K | - | $971.0K | $439.3K | $96.5K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($1.45M) | - | ($7.28M) | ($3.32M) | ($2.67M) | - | ($60.2K) | ($270.3K) | ($1.30M) | - |
| EPS - Basic | ($44.24) | - | ($4.87) | - | - | - | $0.00 | ($0.12) | ($0.22) | - |
| EPS - Diluted | ($2.75) | - | ($4.87) | - | - | - | ($219.38) | ($0.12) | ($0.22) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.84M | $10.47M | $11.44M | $8.06M | $10.52M | $10.88M | $7.45M | $6.65M | $7.83M | - |
| Accounts Receivable | $1.31M | $1.06M | $2.25M | $2.19M | $1.58M | $1.40M | - | - | - | $2.40M |
| Inventory | $1.36M | $863.3K | $2.68M | $2.70M | $3.85M | $2.35M | $2.32M | $2.34M | $2.12M | - |
| Accounts Payable | $3.19M | $2.77M | $2.81M | $3.21M | $2.56M | $2.82M | $2.29M | $3.21M | $2.06M | - |
| Current Assets | $14.38M | $15.48M | $19.16M | $20.99M | $18.24M | $14.79M | $14.42M | $11.74M | $12.15M | - |
| Total Assets | $19.60M | $20.18M | $22.98M | $24.36M | $20.72M | $17.14M | $17.04M | $14.07M | $15.48M | - |
| Current Liabilities | $15.66M | $14.40M | $15.00M | $18.17M | $18.21M | $15.78M | $16.15M | $11.80M | $9.69M | - |
| Long-term Debt | $2.25M | $2.82M | $3.17M | $3.29M | $3.56M | $3.56M | $2.81M | $1.83M | $1.83M | - |
| Total Liabilities | $17.09M | $15.88M | $16.73M | $20.04M | $25.28M | $21.78M | $27.27M | $24.58M | $24.55M | - |
| Stockholders' Equity | $2.51M | $4.30M | $6.26M | $4.31M | ($4.57M) | ($4.64M) | ($10.23M) | ($10.51M) | ($9.07M) | - |
| Retained Earnings | ($44.49M) | ($41.08M) | ($36.82M) | ($27.15M) | ($23.83M) | ($21.16M) | ($15.29M) | ($15.23M) | ($13.66M) | - |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($122.2K) | - | - | - | ($449.1K) | - | - | - | $2.67M | - |
| Investing Cash Flow | ($1.14M) | - | - | - | ($334.7K) | - | - | - | ($332.3K) | - |
| Financing Cash Flow | ($366.1K) | - | - | - | $2.52M | - | - | - | $92.1K | - |
| CapEx | $78.2K | - | - | - | $64.2K | - | - | - | $332.3K | - |
| Free Cash Flow | ($200.4K) | - | - | - | ($513.3K) | - | - | - | $2.34M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 53.4% | - | 69.3% | 44.4% | 68.0% | - | 125.7% | 48.8% | 60.9% | - |
| Operating margin | -25.8% | - | -27.1% | -43.4% | -22.9% | - | 25.4% | -14.9% | -18.8% | - |
| EBITDA margin | -16.0% | - | -26.8% | -43.1% | -20.8% | - | - | - | -18.1% | - |
| Net margin | -28.8% | - | -177.3% | -77.0% | -49.5% | - | -1.8% | -5.1% | -26.0% | - |
| Free cash flow margin | -4.0% | - | - | - | -9.5% | - | - | - | 46.6% | - |
| FCF / Net income | 0.14 | - | - | - | 0.19 | - | - | - | -1.79 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 63.4% | - | 81.3% | 61.2% | 50.6% | - | 46.0% | 38.3% | 36.4% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -7.4% | - | -31.7% | -13.6% | -12.9% | - | -0.4% | -1.9% | -8.4% | - |
| Return on equity | -57.7% | - | -116.3% | -77.0% | 58.5% | - | 0.6% | 2.6% | 14.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.92 | 1.07 | 1.28 | 1.16 | 1.00 | 0.94 | 0.89 | 0.99 | 1.25 | - |
| Quick ratio | 0.83 | 1.01 | 1.10 | 1.01 | 0.79 | 0.79 | 0.75 | 0.80 | 1.04 | - |
| Cash ratio | 0.56 | 0.73 | 0.76 | 0.44 | 0.58 | 0.69 | 0.46 | 0.56 | 0.81 | - |
| Leverage | ||||||||||
| Debt / Equity | 0.90 | 0.66 | 0.51 | 0.76 | -0.78 | -0.77 | -0.27 | -0.17 | -0.20 | - |
| Debt / Assets | 0.11 | 0.14 | 0.14 | 0.14 | 0.17 | 0.21 | 0.16 | 0.13 | 0.12 | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -6.2x | - | -10.3x | -1.2x | -31.7x | - | 0.9x | -1.8x | -9.8x | - |
| Equity multiplier | 7.82 | 4.69 | 3.67 | 5.65 | -4.54 | -3.69 | -1.67 | -1.34 | -1.71 | - |
| Liabilities / Assets | 0.87 | 0.79 | 0.73 | 0.82 | 1.22 | 1.27 | 1.60 | 1.75 | 1.59 | - |
| Efficiency | ||||||||||
| Asset turnover | 0.26 | - | 0.18 | 0.18 | 0.26 | - | 0.20 | 0.37 | 0.32 | - |
| Inventory turnover | 1.72 | - | 0.47 | 0.89 | 0.45 | - | 0.83 | 0.79 | 0.92 | - |
| Days sales outstanding | 96d | - | 200d | 185d | 107d | - | - | - | - | - |
| Days inventory outstanding | 212d | - | 776d | 411d | 815d | - | 441d | 459d | 395d | - |
| Days payable outstanding | 498d | - | 816d | 488d | 542d | - | 434d | 631d | 384d | - |
| Cash conversion cycle | -190d | - | 160d | 107d | 380d | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -6.8% | - | 19.6% | -18.3% | 7.5% | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -26.8% | - | -34.0% | -25.7% | 20.0% | - | - | - | - | - |
| Operating income growth (YoY) | -4.9% | - | - | -138.2% | -30.8% | - | - | - | - | - |
| Net income growth (YoY) | 45.8% | - | -11995.1% | -1128.6% | -105.1% | - | - | -63.3% | -397.7% | - |
| EPS growth (YoY) | - | - | 97.8% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 61.0% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | 49.7% | - | -77.8% | -130.5% | -29.4% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$18.88M totalGolf Simulators$14.68M · 77.8%
Content Software Subscriptions$3.71M · 19.7%
Other$473.6K · 2.5%
Franchise Revenue$13.1K · 0.1%
Peer comparison
Same SIC group: Sporting & Athletic Goods, NEC
Comparing Deep Medicine Acquisition Corp. against the 5 most active filers in the same SIC group.